Liquidia Shares Rise Nearly 27% Following Settlement with United Therapeutics
Shares of Liquidia Corporation (LQDA) surged nearly 27% on Wednesday after the company announced a global settlement resolving all pending litigation with United Therapeutics. The resolution removes legal uncertainty that had previously weighed on investor sentiment, leading to strong gains in stock price. The commercial-stage biopharmaceutical firm closed at $33.94 per share, up by $7.13 from the previous day's close. This settlement is expected to allow Liquidia to focus more fully on its business operations and growth initiatives without ongoing legal distractions. Investors responded positively to the news, signaling confidence in the company’s future prospects following this resolution.
Tickers: $LQDA
Topics: biopharmaceutical litigation resolution
Read the full article at Seeking Alpha
Part of the story Liquidia Shares Rise Over 42% Following Settlement with United Therapeutics (3 articles)